Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial

Laurent F. Martin, Amol M. Patwardhan, Sejal V. Jain, Michelle M. Salloum, Julia Freeman, Rajesh Khanna, Pooja Gannala, Vasudha Goel, Felesia N. Jones-MacFarland, William D.S. Killgore, Frank Porreca, Mohab M. Ibrahim

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Pharmacological management of migraine can be ineffective for some patients. We previously demonstrated that exposure to green light resulted in antinociception and reversal of thermal and mechanical hypersensitivity in rodent pain models. Given the safety of green light emitting diodes, we evaluated green light as a potential therapy in patients with episodic or chronic migraine. Material and methods: We recruited (29 total) patients, of whom seven had episodic migraine and 22 had chronic migraine. We used a one-way cross-over design consisting of exposure for 1–2 hours daily to white light emitting diodes for 10 weeks, followed by a 2-week washout period followed by exposure for 1–2 hours daily to green light emitting diodes for 10 weeks. Patients were allowed to continue current therapies and to initiate new treatments as directed by their physicians. Outcomes consisted of patient-reported surveys. The primary outcome measure was the number of headache days per month. Secondary outcome measures included patient-reported changes in the intensity and frequency of the headaches over a two-week period and other quality of life measures including ability to fall and stay asleep, and ability to perform work. Changes in pain medications were obtained to assess potential reduction. Results: When seven episodic migraine and 22 chronic migraine patients were analyzed as separate cohorts, white light emitting diodes produced no significant change in headache days in either episodic migraine or chronic migraine patients. Combining data from the episodic migraine and chronic migraine groups showed that white light emitting diodes produced a small, but statistically significant reduction in headache days from (days ± SEM) 18.2 ± 1.8 to 16.5 ± 2.01 days. Green light emitting diodes resulted in a significant decrease in headache days from 7.9 ± 1.6 to 2.4 ± 1.1 and from 22.3 ± 1.2 to 9.4 ± 1.6 in episodic migraine and chronic migraine patients, respectively. While some improvement in secondary outcomes was observed with white light emitting diodes, more secondary outcomes with significantly greater magnitude including assessments of quality of life, Short-Form McGill Pain Questionnaire, Headache Impact Test-6, and Five-level version of the EuroQol five-dimensional survey without reported side effects were observed with green light emitting diodes. Conclusions regarding pain medications reduction with green light emitting diode exposure were not possible. No side effects of light therapy were reported. None of the patients in the study reported initiation of new therapies. Discussion: Green light emitting diodes significantly reduced the number of headache days in people with episodic migraine or chronic migraine. Additionally, green light emitting diodes significantly improved multiple secondary outcome measures including quality of life and intensity and duration of the headache attacks. As no adverse events were reported, green light emitting diodes may provide a treatment option for those patients who prefer non-pharmacological therapies or may be considered in complementing other treatment strategies. Limitations of this study are the small number of patients evaluated. The positive data obtained support implementation of larger clinical trials to determine possible effects of green light emitting diode therapy. This study is registered with clinicaltrials.gov under NCT03677206.

Original languageEnglish (US)
Pages (from-to)135-147
Number of pages13
JournalCephalalgia
Volume41
Issue number2
DOIs
StatePublished - Feb 2021

Bibliographical note

Funding Information:
The authors would like to thank Vangie Steinbrenner for her valuable assistance with obtaining the IRB for this study. We also would like to thank Debbie Schaab, RN, for her tireless efforts to follow-up with patients and her overall help with this study. We thank Scott Derigne for his help with the LED strips. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by support from NCCIH R01AT009716 (to MMI), the Comprehensive Chronic Pain and Addiction Center-University of Arizona, and the University of Arizona CHiLLi initiative.

Publisher Copyright:
© International Headache Society 2020.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Keywords

  • Green light
  • light therapy
  • migraine
  • non-pharmacological therapy

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial'. Together they form a unique fingerprint.

Cite this